An Open-label, Multi-Center, Phase IIIb Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia Who Are Eligible for "7+3" or "5+2" Chemotherapy
收藏DataCite Commons2026-03-27 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00012918/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study was to gather and evaluate additional safety and efficacy data on the combination of midostaurin and standard of care for adult patients with newly diagnosed Fms-like tyrosine kinase receptor (FLT3) mutated Acute Myeloid Leukemia (AML) who were eligible for standard induction and consolidation
提供机构：
Vivli
创建时间：
2026-03-27
